METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE
The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α-Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., a...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SOUBERBIELLE, Bernard PASSALACQUA, Cristobal HUSTON, Marshall |
| description | The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α-Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., an AAV expression vector) comprising an α galactosidase A (α-Gal A) expression cassette, which comprises an α galactosidase A (α-Gal A) transgene encoding the at least one α-Gal A protein at a dose of about 5×1012 vector genomes per kilogram of body weight (vg/kg) to about 5×1013 vg/kg.
La présente divulgation concerne les procédés pour traiter ou atténuer un ou plusieurs symptômes de la maladie de Fabry, réduire la quantité de glycosphingolipides, et/ou augmenter une activité de protéine α galactosidase A (α-Gal A) chez un sujet en ayant besoin, en administrant les vecteurs d'expression (par ex, un vecteur d'expression AAV) comprenant une cassette d'expression α galactosidase A (α-Gal A), qui comprend un transgène α galactosidase A (α-Gal A) codant pour au moins une protéine α-Gal A à une dose allant d'environ 5×1012 vecteurs génomiques par kilogramme de poids corporel (vg/kg) à environ 5×1013 vg/kg. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023081781A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023081781A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023081781A13</originalsourceid><addsrcrecordid>eNrjZPD1dQ3x8HcJVnDzD1IIDXZV8HdTCPMMcvRRCHN1DgGKOfv7BYcEhTqHQJSEeLgqhAS5Oob4uvqFgBS7OToFRSq4eAa7Oga78jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwMjYwMLQ3MLQ0dDY-JUAQCWrS8N</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE</title><source>esp@cenet</source><creator>SOUBERBIELLE, Bernard ; PASSALACQUA, Cristobal ; HUSTON, Marshall</creator><creatorcontrib>SOUBERBIELLE, Bernard ; PASSALACQUA, Cristobal ; HUSTON, Marshall</creatorcontrib><description>The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α-Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., an AAV expression vector) comprising an α galactosidase A (α-Gal A) expression cassette, which comprises an α galactosidase A (α-Gal A) transgene encoding the at least one α-Gal A protein at a dose of about 5×1012 vector genomes per kilogram of body weight (vg/kg) to about 5×1013 vg/kg.
La présente divulgation concerne les procédés pour traiter ou atténuer un ou plusieurs symptômes de la maladie de Fabry, réduire la quantité de glycosphingolipides, et/ou augmenter une activité de protéine α galactosidase A (α-Gal A) chez un sujet en ayant besoin, en administrant les vecteurs d'expression (par ex, un vecteur d'expression AAV) comprenant une cassette d'expression α galactosidase A (α-Gal A), qui comprend un transgène α galactosidase A (α-Gal A) codant pour au moins une protéine α-Gal A à une dose allant d'environ 5×1012 vecteurs génomiques par kilogramme de poids corporel (vg/kg) à environ 5×1013 vg/kg.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230511&DB=EPODOC&CC=WO&NR=2023081781A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230511&DB=EPODOC&CC=WO&NR=2023081781A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SOUBERBIELLE, Bernard</creatorcontrib><creatorcontrib>PASSALACQUA, Cristobal</creatorcontrib><creatorcontrib>HUSTON, Marshall</creatorcontrib><title>METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE</title><description>The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α-Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., an AAV expression vector) comprising an α galactosidase A (α-Gal A) expression cassette, which comprises an α galactosidase A (α-Gal A) transgene encoding the at least one α-Gal A protein at a dose of about 5×1012 vector genomes per kilogram of body weight (vg/kg) to about 5×1013 vg/kg.
La présente divulgation concerne les procédés pour traiter ou atténuer un ou plusieurs symptômes de la maladie de Fabry, réduire la quantité de glycosphingolipides, et/ou augmenter une activité de protéine α galactosidase A (α-Gal A) chez un sujet en ayant besoin, en administrant les vecteurs d'expression (par ex, un vecteur d'expression AAV) comprenant une cassette d'expression α galactosidase A (α-Gal A), qui comprend un transgène α galactosidase A (α-Gal A) codant pour au moins une protéine α-Gal A à une dose allant d'environ 5×1012 vecteurs génomiques par kilogramme de poids corporel (vg/kg) à environ 5×1013 vg/kg.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPD1dQ3x8HcJVnDzD1IIDXZV8HdTCPMMcvRRCHN1DgGKOfv7BYcEhTqHQJSEeLgqhAS5Oob4uvqFgBS7OToFRSq4eAa7Oga78jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwMjYwMLQ3MLQ0dDY-JUAQCWrS8N</recordid><startdate>20230511</startdate><enddate>20230511</enddate><creator>SOUBERBIELLE, Bernard</creator><creator>PASSALACQUA, Cristobal</creator><creator>HUSTON, Marshall</creator><scope>EVB</scope></search><sort><creationdate>20230511</creationdate><title>METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE</title><author>SOUBERBIELLE, Bernard ; PASSALACQUA, Cristobal ; HUSTON, Marshall</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023081781A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>SOUBERBIELLE, Bernard</creatorcontrib><creatorcontrib>PASSALACQUA, Cristobal</creatorcontrib><creatorcontrib>HUSTON, Marshall</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SOUBERBIELLE, Bernard</au><au>PASSALACQUA, Cristobal</au><au>HUSTON, Marshall</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE</title><date>2023-05-11</date><risdate>2023</risdate><abstract>The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α-Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., an AAV expression vector) comprising an α galactosidase A (α-Gal A) expression cassette, which comprises an α galactosidase A (α-Gal A) transgene encoding the at least one α-Gal A protein at a dose of about 5×1012 vector genomes per kilogram of body weight (vg/kg) to about 5×1013 vg/kg.
La présente divulgation concerne les procédés pour traiter ou atténuer un ou plusieurs symptômes de la maladie de Fabry, réduire la quantité de glycosphingolipides, et/ou augmenter une activité de protéine α galactosidase A (α-Gal A) chez un sujet en ayant besoin, en administrant les vecteurs d'expression (par ex, un vecteur d'expression AAV) comprenant une cassette d'expression α galactosidase A (α-Gal A), qui comprend un transgène α galactosidase A (α-Gal A) codant pour au moins une protéine α-Gal A à une dose allant d'environ 5×1012 vecteurs génomiques par kilogramme de poids corporel (vg/kg) à environ 5×1013 vg/kg.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023081781A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T12%3A40%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SOUBERBIELLE,%20Bernard&rft.date=2023-05-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023081781A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |